Indication
KRAS wild type Allele
1 clinical trial
3 products
Clinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
CetuximabProduct
IrinotecanProduct
Vemurafenib